Advanced search
Publication Cover
Clinical Toxicology Volume 60, 2022 - Issue 10
Submit an article Journal homepage
394
Views
0
CrossRef citations to date
0
Altmetric
Clinical Research

Clinical features associated with ADB-BUTINACA exposure in patients attending emergency departments in England

A. Kinga Newcastle Hospitals NHS Foundation Trust, Newcastle, United KingdomCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-0813-3567View further author information
ORCID Icon,
S. L. Hilla Newcastle Hospitals NHS Foundation Trust, Newcastle, United Kingdom;b Translational and Clinical Research Institute, Newcastle University, Newcastle, United KingdomView further author information
,
M. Puccic University Hospitals Birmingham NHS Foundation Trust, Birmingham, United KingdomView further author information
,
G. Baileyd Imperial College Healthcare NHS Trust, London, United KingdomView further author information
,
L. Keatinge Royal Berkshire NHS Foundation Trust, Reading, United KingdomORCID Iconhttps://orcid.org/0000-0001-9028-2520View further author information
ORCID Icon,
R. Macfarlanef Epsom and St Helier NHS Trust, Epsom, United KingdomView further author information
,
F. Cantleg King's College Hospital NHS Foundation Trust, London, United KingdomView further author information
,
S. Hudsonh Sport and Specialised Analytical Services, Fordham, United KingdomView further author information
&
S. H. L. Thomasa Newcastle Hospitals NHS Foundation Trust, Newcastle, United Kingdom;b Translational and Clinical Research Institute, Newcastle University, Newcastle, United KingdomORCID Iconhttps://orcid.org/0000-0002-0581-6389View further author information
ORCID Icon show all
Pages 1094-1098 | Received 04 Apr 2022, Accepted 10 Jul 2022, Published online: 09 Aug 2022

References

  • Banister SD, Connor M. The chemistry and pharmacology of synthetic cannabinoid receptor agonists as new psychoactive substances: origins. Handb Exp Pharmacol. 2018;252:165–190.
  • Tait RJ, Caldicott D, Mountain D, et al. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol. 2016;54(1):1–13.
  • European Monitoring Centre for Drugs and Drug Addiction. European drug report 2021: trends and developments, publications office of the European Union, Luxembourg; 2021. [cited 2022 March 11]. Available from: https://www.emcdda.europa.eu/system/files/publications/13838/TDAT21001ENN.pdf.
  • Cannaert A, Sparkes E, Pike E, et al. Synthesis and in vitro cannabinoid receptor 1 activity of recently detected synthetic cannabinoids 4F-MDMB-BICA, 5F-MPP-PICA, MMB-4en-PICA, CUMYL-CBMICA, ADB-BINACA, APP-BINACA, 4F-MDMB-BINACA, MDMB-4en-PINACA, A-CHMINACA, 5F-AB-P7AICA, 5F-MDMB-P7AICA, and 5F-AP7AICA. ACS Chem Neurosci. 2020;11(24):4434–4446.
  • Kavanagh P, Pechnikov A, Nikolaev I, et al. Detection of ADB-BUTINACA metabolites in human urine, blood, kidney and liver. J Anal Toxicol. 2022;46(6):641–650.
  • European Monitoring Centre for Drugs and Drug Addiction. Formal notification of N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-butyl1H-indazole-3-carboxamide (ADB-BUTINACA) by Sweden as a new psychoactive substance under the terms of Regulation (EU) 2017/2101. 2019. EU-EWS-RCS-FN-2019-0042.
  • Norman C, Halter S, Haschimi B, et al. A transnational perspective on the evolution of the synthetic cannabinoid receptor agonists market: comparing prison and general populations. Drug Test Anal. 2021;13(4):841–852.
  • NPS Discovery. Synthetic cannabinoids in the Unbited States. Trend report Q4; 2021. [cited 2022 March 11]. Available from: https://www.npsdiscovery.org/wp-content/uploads/2022/02/2021-Q4_Synthetic-Cannabinoids_Trend-Report.pdf.
  • Haden M, Cashman J, Ketchin A, et al. Detection of flubromazolam in patients with suspected non-medical drug use attending emergency departments in the United Kingdom. Clin Toxicol. 2022;60(1):33–37.
  • Advisory Council on the Misuse of Drugs. Synthetic cannabinoid receptor agonists. 28 October 2020. London: Home Office; 2020. [cited 2022 March 11]. Available from: https://www.gov.uk/government/publications/synthetic-cannabinoid-receptor-agonists.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.